Adducts of trans-4-Hydroxynonenal
A R T I C L E S
5*-OH and 2*-OH), 4.58-4.40 (m,1H, 1*-OH), 4.32 (m, 1H, H-3′),
4.013 and 3.99 (diastereomers, m, m, 1H, H-4*), 3.79 (m, 1H, H-4′),
3.63-3.42 (m, 4H, H-5′, H-5′′, H-2*, H-5*), 3.30-3.19 (m, 2H, H-1*,
H-1**, hidden under DMSO peak but visible in CD3OD), 2.58 (m,
1H, H-2′), 2.18 (m, 1H, H-2′′), 1.78 (m, 1H, H-3*), 1.57-1.14 (m,
9H), 0.85 (t, J ) 6.6 Hz, 3H); HRMS (FAB, NBA) m/z calcd for
C20H34N5O7 (M+H) 456.2458, found 456.2440.
overlapped with H-5′), 3.72 (dd, J ) 12.0, 3.9 Hz, 1H, H-5′′), 3.75-
3.70 (m, 1H, H-6, overlapped with H-5′′), 2.67 (m, 1H, H-2′), 2.33
(m, 1H, H-2′′), 2.10 (m, 1H, H-7a), 1.74 (m, 1H, H-7b), 1.57-1.27
(m, 8H), 0.923 (t, J ) 6.5 Hz, 3H); HRMS (FAB, NBA) m/z calcd for
C19H30N5O6 (M+H) 424.2196, found 424.2190.
3-(2-Deoxy-â-D-erythro-pentofuranosyl)-5,6,7,8-tetrahydro-6-(S)-
[1-(R)-hydroxyhexyl]pyrimido[1,2-a]purin-10(3H)-one (2). Following
the procedure described below for 4, 28 was converted to 2 in 84%
N2-[1-(S)-(2,3-Dihydroxypropyl)-2-(R)-hydroxyheptyl]deoxygua-
nosine (28). A solution of (4S,5R)-9 (10.0 mg, 0.049 mmol) in
anhydrous DMSO (200 µL) was added to a mixture of 5a (11.9 mg,
0.032 mmol), DMSO (100 µL), and diisopropylethylamine (100 µL).
The mixture was stirred at 65-70 °C for 2 days, then cooled, and
concentrated under high vacuum using a centrifugal evaporator. The
residue was dissolved in 5% acetic acid (1 mL) and stirred at room
temperature for 1 h. Purification by HPLC (gradient B) gave 28 (8.3
mg, 57%): 1H NMR (DMSO-d6) δ 10.41 (m, 1H, N1-H), 7.88 and
7.87 (diastereomers, s, s, 1H, H-8), 6.41-6.33 (m, 1H, N2-H), 6.12-
6.08 (m, 1H, H-1′), 5.25 (d, J ) 4.0 Hz, 1H, 3′-OH), 4.87-4.80 (m,
2H, 5′-OH and 5*-OH), 4.73-4.63 (m, 1H, 2*-OH), 4.51 and 4.45
(diastereomers, t, t, J ) 5.6 and 5.5 Hz, 1H, 1*-OH), 4.32 (m, 1H,
H-3′), 4.02 and 3.91 (diastereomers, m, m, 1H, H-4*), 3.79 (m, 1H,
H-4′), 3.57-3.44 (m, 4H, H-5′, H-5′′, H-2*, H-5*), 3.26 (m, 2H, H-1*,
H-1**, hidden under DMSO peak but visible in CD3OD), 2.57 (m,
1H, H-2′), 2.17 (m, 1H, H-2′′), 1.79 (m, 1H, H-3*), 1.57-1.23 (m,
9H), 0.85 (t, J ) 6.6 Hz, 3H); HRMS (FAB, NBA) m/z calcd for
C20H34N5O7 (M+H) 456.2458, found 456.2450.
1
yield. H NMR (CD3OD) δ 7.91 (s, 1H, H-2), 6.42 (t, J ) 2.5, 1H,
H-8), 6.24 (dd, J ) 7.6, 6.2 Hz, 1H, H-1′), 4.51 (m, 1H, H-3′), 3.98
(m, 1H, H-4′), 3.78 (dd, J ) 12.0, 3.4 Hz, 1H, H-5′), 3.81-3.75 (m,
1H, H-11, overlapped with H-5′), 3.73 (dd, 12.0, 3.9 Hz, 1H, H-5′′),
3.75-3.70 (m, 1H, H-6, overlapped with H-5′′), 2.69 (m, 1H, H-2′),
2.33 (m, 1H, H-2′′), 2.11 (m, 1H, H-7a), 1.74 (m, 1H, H-7b), 1.57-
1.28 (m, 8H), 0.93 (t, J ) 6.7 Hz, 3H); HRMS (FAB, NBA) m/z calcd
for C19H30N5O6 (M+H) 424.2196, found 424.2177.
3-(2-Deoxy-â-D-erythro-pentofuranosyl)-5,6,7,8-tetrahydro-6-(R)-
[1-(R)-hydroxyhexyl]pyrimido[1,2-a]purin-10(3H)-one (3). Following
the procedure described below for 4, 29 was converted to 3 in 83%
1
yield. H NMR (CD3OD) δ 7.91 (s, 1H, H-2), 6.40 (t, J ) 2.5, 1H,
H-8), 6.23 (t, J ) 6.9 Hz, 1H, H-1′), 4.51 (m, 1H, H-3′), 3.98 (dt, J )
3.3, 3.0 Hz, 1H, H-4′), 3.78 (dd, J ) 12.1, 3.4 Hz,1H, H-5′), 3.70 (dd,
J ) 12.1, 3.8 Hz, 1H, H-5′′), 3.61 (m, 1H, H-6), 3.47 (m, 1H, H-11),
2.68 (m, 1H, H-2′), 2.33 (m, 1H, H-2′′), 2.18 (m, 1H, H-7a), 1.64-
1.28 (m, 9H), 0.93 (t, J ) 6.6 Hz, 3H); HRMS (FAB, NBA) m/z calcd
for C19H30N5O6 (M+H) 424.2196, found 424.2192.
N2-[1-(R)-(2,3-Dihydroxypropyl)-2-(R)-hydroxyheptyl]deoxygua-
nosine (29). Following the procedure described below for 30, the
reaction of (4R,5R)-28 (15.2 mg, 0.074 mmol) with 5a (13.7 mg, 0.037
mmol) gave 29 (10.7 mg, 63.5%) after hydrolysis of the O6-trimeth-
ylsilylethyl group. 1H NMR (DMSO-d6) δ 10.35 (m, 1H, N1-H), 7.89
and 7.86 (diastereomers, s, s, 1H, H-8), 6.34 (m, 1H, N2-H), 6.08 (m,
1H, H-1′), 5.24 (m, 1H, 3′-OH), 4.99 and 4.90 (diastereomers, m, 1H,
5*-OH), 4.88 (m, 1H, 5′-OH), 4.60 and 4.49 (diastereomers, s, s, 1H,
2*-OH), 4.47 (m, 1H, 1*-OH), 4.33 (m, 1H, H-3′), 4.11-4.05 (m, 1H,
H-4*), 3.79 (m, 1H, H-4′), 3.60-3.40 (m, 4H, H-5′, H-5′′, H-2*, H-5*),
3.30-3.15 (m, 2H, H-1*, H-1**, hidden under water peak but visible
in CD3OD), 2.58 (m, 1H, H-2′), 2.18 (m, 1H, H-2′′), 1.72 (m, 1H,
H-3*), 1.50-1.10 (m, 9H), 0.81 (t, J ) 6.8 Hz, 3H); HRMS (FAB,
NBA) m/z calcd for C20H34N5O7 (M+H) 456.2458, found 456.2439.
N2-[1-(S)-(2,3-Dihydroxypropyl)-2-(S)-hydroxyheptyl]deoxygua-
nosine (30). A solution of (4S,5S)-11 (20.1 mg, 0.098 mmol) in
anhydrous DMSO (200 µL) was added to a solution of 5a (18.2 mg,
0.049 mmol), DMSO (100 µL), and diisopropylethylamine (100 µL).
The mixture was stirred at 70-75 °C for 26 h, cooled, and concentrated
under high vacuum using a centrifugal evaporator. The residue was
dissolved in 5% acetic acid (1 mL) and stirred at room temperature for
1 h. Purification by HPLC (gradient A) gave 30 (13.5 mg, 60.5%) as
3-(2-Deoxy-â-D-erythro-pentofuranosyl)-5,6,7,8-tetrahydro-6-(S)-
[1-(S)-hydroxyhexyl]pyrimido[1,2-a]purine-10(3H)-one (4). A solu-
tion of sodium periodate (505 µL, 0.0101 mmol, 20 mM in water) was
added to a solution of 30 (4.6 mg, 0.010 mmol) in 50 mM, pH 7
phosphate buffer (500 µL). The reaction mixture was stirred at room
temperature for 10 min and immediately purified by HPLC (gradient
1
A) to give 4 (3.7 mg, 87%). H NMR (CD3OD) δ 7.91 (s, 1H, H-2),
6.40 (t, J ) 2.5 Hz, 1H, H-8), 6.23 (t, J ) 6.9 Hz, 1H, H-1′), 4.51 (m,
1H, H-3′), 3.99 (m, H-4′), 3.78 (dd, J ) 12.1, 3.4 Hz, H-5′), 3.71 (dd,
J ) 12.1, 3.7 Hz, 1H, H-5′′), 3.61 (m, 1H, H-6), 3.47 (m, 1H, H-11),
2.68 (m, 1H, H-2′), 2.33 (m, 1H, H-2′′), 2.19 (m, 1H, H-7a), 1.64-
1.28 (m, 9H), 0.93 (t, J ) 6.6 Hz, 3H); HRMS (FAB, NBA) m/z calcd
for C19H30N5O6 (M+1) 424.2196, found 424.2181.
3-(2-deoxy-â-D-erythro-pentofuranosyl)-6-(S)-[1-(S)-hydroxyhexyl)]-
5,6,7,8-tetrahydro-8-(R)-(N2-deoxyguanosinyl)-pyrimido[1,2-a]pu-
rin-10(3H)-one (45c). In a glass tube was added 4 (5 mg) and 2′-
deoxyguanosine monohydrate (10 mg) in DMSO (250 µL). The mixture
was stirred in an oil bath at 100 °C for 11 days. The solvent was
removed under vacuum. Purification by HPLC (gradient B) gave
recovered 4 (3 mg) and 45c (0.7 mg, 9%): 1H NMR (DMSO-d6) δ
10.20 (s, 1H), 7.97 (s, 1H), 7.94 (s, 1H), 7.43 (s, 1H), 7.31 (d, J ) 6.8
Hz, 1 H), 6.66 (m, 1H), 6.20 (m, 1H), 6.13 (m, 1H), 5.31 (d, J ) 4.0
Hz, 1H), 5.25 (d, J ) 3.7 Hz), 5.03 (d, J ) 5.5 Hz, 1H), 4.96 (t, J )
5.4 Hz), 4.88 (t, J ) 5.6 Hz, 1H), 4.36 (m, 1H), 3.90 (m, 1H), 3.52
(m, 6H), 2.62 (m, 1H), 2.44 (m, 1H, hidden under solvent peak, visible
in COSY spectrum), 2.20 (m, 3H), 1.65 (m, 1H), 1.38-1.10 (m, 9H),
1
a mixture of diastereomers. H NMR (DMSO-d6) δ 10.37 (br s, 1H,
N1-H), 7.88 and 7.86 (diastereomers, s, s, 1H, H-8), 6.39 (m, 1H,
N2-H), 6.10 (m, 1H, H-1′), 5.26 (m, 1H, 3′-OH), 4.99 and 4.90
(diastereomers, d, d, J ) 4.2 and 4.2 Hz, 1H, 5*-OH), 4.88 (m, 1H,
5′-OH), 4.58 and 4.45-4.38 (diastereomers, d, d, J ) 4.5 and 4.5 Hz,
1H, 2*-OH, the later peak overlapped with 1*-OH), 4.48 (m, 1H,
1*-OH), 4.33 (m, 1H, H-3′), 4.11-4.03 (m, 1H, H-4*), 3.80 (m, 1H,
H-4′), 3.60-3.40 (m, 4H, H-5′, H-5′′, H-2*, H-5*), 3.30-3.15 (m, 2H,
H-1*, H-1**, hidden under water peak but visible in CD3OD), 2.58
(m, 1H, H-2′), 2.16 (m, 1H, H-2′′, 1.72(m, 1H, H-3*), 1.50-1.10 (m,
9H), 0.80 (t, J ) 6.7 Hz, 3H); HRMS (FAB, NBA) m/z calcd for
C20H34N5O7 (M+H) 456.2458, found 456.2471.
3-(2-Deoxy-â-D-erythro-pentofuranosyl)-5,6,7,8-tetrahydro-6-(R)-
[1-(S)-hydroxyhexyl]pyrimido[1,2-a]purin-10(3H)-one (1). Following
the same procedure described below for 4, 27 was converted to 1 in
80% yield. 1H NMR (CD3OD) δ 7.91 (s, 1H, H-2), 6.42 (m, 1H, H-8),
6.23 (dd, J ) 7.5, 6.5 Hz, 1H, H-1′), 4.51 (m, 1H, H-3′), 3.98 (m, 1H,
H-4′), 3.78 (dd, J ) 12.0, 3.5 Hz, 1H, H-5′), 3.82-3.75 (m, 1H, H-11,
0.84 (t, J ) 6.7 Hz, 1H); MS: LC-ESMS m/z calcd for C29H N10O9
41
(M+1) 673.31, found 673.38.
Synthesis of 5′-d(GCTAGC(27)AGTCC) (34). The oligonucleotide
5′-d(GCTAGC(X)AGTCC) (33, X ) 5a; 10 A260 units) was mixed in
a plastic tube with diisopropylethylamine (50 µL), DMSO (100 µL),
and 1 (0.5 mg). The mixture was stirred at 65 °C for 72 h, adding
additional portions of 1 (0.5 mg) after 24 and 48 h. HPLC showed the
disappearance of 33. The solvent was evaporated under vacuum and
the residue dissolved in 5% acetic acid (500 µL), then stirred for 2 h
at room temperature. The reaction mixture was neutralized to pH 7
(pH paper) with 1 M NaOH and purified by HPLC (gradient A) to
give oligonucleotide 27 (5.4 A260 units, 54%). The modified oligo-
nucleotide (27) was characterized by enzyme digestion followed by
9
J. AM. CHEM. SOC. VOL. 125, NO. 19, 2003 5699